Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 27.3% | -33.1% | -18.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 93.4% | 73.3% | 73.1% | 74.3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | $0 | $0 | $0 |
| % Margin | -13.5% | 9.1% | 1.5% | 43% |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$0 | $0 | -$0 | $0 |
| % Margin | -2.4% | 39.7% | -17% | 23.7% |
| EPS | -0.22 | 3.02 | -1.98 | 3.46 |
| % Growth | -107.3% | 252.5% | -157.2% | – |
| EPS Diluted | -0.22 | 2.94 | -1.98 | 3.34 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 24.4% | 76.8% | 41.4% | 59.1% |